Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019
With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. I...
Gespeichert in:
Veröffentlicht in: | Journal of dermatology 2020-02, Vol.47 (2), p.89-103 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 103 |
---|---|
container_issue | 2 |
container_start_page | 89 |
container_title | Journal of dermatology |
container_volume | 47 |
creator | Nakamura, Yasuhiro Asai, Jun Igaki, Hiroshi Inozume, Takashi Namikawa, Kenjiro Hayashi, Ayato Fukushima, Satoshi Fujimura, Taku Ito, Takamichi Imafuku, Keisuke Tanaka, Ryota Teramoto, Yukiko Minagawa, Akane Miyagawa, Takuya Miyashita, Azusa Wada, Makoto Koga, Hiroshi Sugaya, Makoto |
description | With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach. |
doi_str_mv | 10.1111/1346-8138.15151 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2320375878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2320375878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5021-dbd5e7eb3959f71d02198c1ff0b3352234e8dd35da6c4edd5f1db2be5eac16283</originalsourceid><addsrcrecordid>eNqFkM9PwjAYhhujEUTP3kwTL14G_UG3zhsRRAkJFz03XfuNjGwU1y2G_97CkIMX20O_vHn65MuL0D0lQxrOiPJxHEnK5ZCKcC9Q_5xcoj7hUkRsTJIeuvF-QwhLBSXXqMdpIhmVcR9lC73TW_CAp1BXunGlWxdGl3jivTOFbgq3xfO2sFAWAXvGq7Y5TtjleH3Oce5qbNomqFzrcQWl3rpKY0Zoeouucl16uDu9A_T5Ovt4eYuWq_n7y2QZGUEYjWxmBSSQ8VSkeUJtyFJpaJ6TjHPBGB-DtJYLq2MzBmtFTm3GMhCgDY2Z5AP01Hl3tftqwTeqKryBsuyWUowzwhMhkwP6-AfduLbehu0CJQjlhMQ8UKOOMrXzvoZc7eqi0vVeUaIO9atD2epQtjrWH348nLxtVoE98799B0B0wHdRwv4_n1pMZ534B8oAjtE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350130063</pqid></control><display><type>article</type><title>Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Nakamura, Yasuhiro ; Asai, Jun ; Igaki, Hiroshi ; Inozume, Takashi ; Namikawa, Kenjiro ; Hayashi, Ayato ; Fukushima, Satoshi ; Fujimura, Taku ; Ito, Takamichi ; Imafuku, Keisuke ; Tanaka, Ryota ; Teramoto, Yukiko ; Minagawa, Akane ; Miyagawa, Takuya ; Miyashita, Azusa ; Wada, Makoto ; Koga, Hiroshi ; Sugaya, Makoto</creator><creatorcontrib>Nakamura, Yasuhiro ; Asai, Jun ; Igaki, Hiroshi ; Inozume, Takashi ; Namikawa, Kenjiro ; Hayashi, Ayato ; Fukushima, Satoshi ; Fujimura, Taku ; Ito, Takamichi ; Imafuku, Keisuke ; Tanaka, Ryota ; Teramoto, Yukiko ; Minagawa, Akane ; Miyagawa, Takuya ; Miyashita, Azusa ; Wada, Makoto ; Koga, Hiroshi ; Sugaya, Makoto</creatorcontrib><description>With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.</description><identifier>ISSN: 0385-2407</identifier><identifier>EISSN: 1346-8138</identifier><identifier>DOI: 10.1111/1346-8138.15151</identifier><identifier>PMID: 31782186</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Best practice ; Cancer therapies ; Clinical trials ; cutaneous melanoma ; Dermatology - standards ; grade system ; guidelines ; Humans ; immune checkpoint inhibitor ; Immune checkpoint inhibitors ; Japan ; Melanoma ; Melanoma - diagnosis ; Melanoma - therapy ; molecular‐targeted agent ; Patient Care Team - standards ; Radiation Oncology - standards ; Skin cancer ; Skin Neoplasms - diagnosis ; Skin Neoplasms - therapy ; Societies, Medical - standards ; Surgery, Plastic - standards</subject><ispartof>Journal of dermatology, 2020-02, Vol.47 (2), p.89-103</ispartof><rights>2019 Japanese Dermatological Association</rights><rights>2019 Japanese Dermatological Association.</rights><rights>Copyright © 2020 Japanese Dermatological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5021-dbd5e7eb3959f71d02198c1ff0b3352234e8dd35da6c4edd5f1db2be5eac16283</citedby><cites>FETCH-LOGICAL-c5021-dbd5e7eb3959f71d02198c1ff0b3352234e8dd35da6c4edd5f1db2be5eac16283</cites><orcidid>0000-0001-7817-624X ; 0000-0002-7887-8126 ; 0000-0001-7054-1863 ; 0000-0002-8855-3288 ; 0000-0003-2763-7346 ; 0000-0002-4471-1635 ; 0000-0002-2679-8546 ; 0000-0002-0704-8037 ; 0000-0002-7610-0820 ; 0000-0003-4222-9762 ; 0000-0001-6809-5833 ; 0000-0002-3664-5818 ; 0000-0003-2805-4177 ; 0000-0001-7983-9746 ; 0000-0002-5125-2932 ; 0000-0002-1618-329X ; 0000-0002-0622-7682</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1346-8138.15151$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1346-8138.15151$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31782186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakamura, Yasuhiro</creatorcontrib><creatorcontrib>Asai, Jun</creatorcontrib><creatorcontrib>Igaki, Hiroshi</creatorcontrib><creatorcontrib>Inozume, Takashi</creatorcontrib><creatorcontrib>Namikawa, Kenjiro</creatorcontrib><creatorcontrib>Hayashi, Ayato</creatorcontrib><creatorcontrib>Fukushima, Satoshi</creatorcontrib><creatorcontrib>Fujimura, Taku</creatorcontrib><creatorcontrib>Ito, Takamichi</creatorcontrib><creatorcontrib>Imafuku, Keisuke</creatorcontrib><creatorcontrib>Tanaka, Ryota</creatorcontrib><creatorcontrib>Teramoto, Yukiko</creatorcontrib><creatorcontrib>Minagawa, Akane</creatorcontrib><creatorcontrib>Miyagawa, Takuya</creatorcontrib><creatorcontrib>Miyashita, Azusa</creatorcontrib><creatorcontrib>Wada, Makoto</creatorcontrib><creatorcontrib>Koga, Hiroshi</creatorcontrib><creatorcontrib>Sugaya, Makoto</creatorcontrib><title>Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019</title><title>Journal of dermatology</title><addtitle>J Dermatol</addtitle><description>With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.</description><subject>Best practice</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>cutaneous melanoma</subject><subject>Dermatology - standards</subject><subject>grade system</subject><subject>guidelines</subject><subject>Humans</subject><subject>immune checkpoint inhibitor</subject><subject>Immune checkpoint inhibitors</subject><subject>Japan</subject><subject>Melanoma</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - therapy</subject><subject>molecular‐targeted agent</subject><subject>Patient Care Team - standards</subject><subject>Radiation Oncology - standards</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - diagnosis</subject><subject>Skin Neoplasms - therapy</subject><subject>Societies, Medical - standards</subject><subject>Surgery, Plastic - standards</subject><issn>0385-2407</issn><issn>1346-8138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM9PwjAYhhujEUTP3kwTL14G_UG3zhsRRAkJFz03XfuNjGwU1y2G_97CkIMX20O_vHn65MuL0D0lQxrOiPJxHEnK5ZCKcC9Q_5xcoj7hUkRsTJIeuvF-QwhLBSXXqMdpIhmVcR9lC73TW_CAp1BXunGlWxdGl3jivTOFbgq3xfO2sFAWAXvGq7Y5TtjleH3Oce5qbNomqFzrcQWl3rpKY0Zoeouucl16uDu9A_T5Ovt4eYuWq_n7y2QZGUEYjWxmBSSQ8VSkeUJtyFJpaJ6TjHPBGB-DtJYLq2MzBmtFTm3GMhCgDY2Z5AP01Hl3tftqwTeqKryBsuyWUowzwhMhkwP6-AfduLbehu0CJQjlhMQ8UKOOMrXzvoZc7eqi0vVeUaIO9atD2epQtjrWH348nLxtVoE98799B0B0wHdRwv4_n1pMZ534B8oAjtE</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Nakamura, Yasuhiro</creator><creator>Asai, Jun</creator><creator>Igaki, Hiroshi</creator><creator>Inozume, Takashi</creator><creator>Namikawa, Kenjiro</creator><creator>Hayashi, Ayato</creator><creator>Fukushima, Satoshi</creator><creator>Fujimura, Taku</creator><creator>Ito, Takamichi</creator><creator>Imafuku, Keisuke</creator><creator>Tanaka, Ryota</creator><creator>Teramoto, Yukiko</creator><creator>Minagawa, Akane</creator><creator>Miyagawa, Takuya</creator><creator>Miyashita, Azusa</creator><creator>Wada, Makoto</creator><creator>Koga, Hiroshi</creator><creator>Sugaya, Makoto</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7817-624X</orcidid><orcidid>https://orcid.org/0000-0002-7887-8126</orcidid><orcidid>https://orcid.org/0000-0001-7054-1863</orcidid><orcidid>https://orcid.org/0000-0002-8855-3288</orcidid><orcidid>https://orcid.org/0000-0003-2763-7346</orcidid><orcidid>https://orcid.org/0000-0002-4471-1635</orcidid><orcidid>https://orcid.org/0000-0002-2679-8546</orcidid><orcidid>https://orcid.org/0000-0002-0704-8037</orcidid><orcidid>https://orcid.org/0000-0002-7610-0820</orcidid><orcidid>https://orcid.org/0000-0003-4222-9762</orcidid><orcidid>https://orcid.org/0000-0001-6809-5833</orcidid><orcidid>https://orcid.org/0000-0002-3664-5818</orcidid><orcidid>https://orcid.org/0000-0003-2805-4177</orcidid><orcidid>https://orcid.org/0000-0001-7983-9746</orcidid><orcidid>https://orcid.org/0000-0002-5125-2932</orcidid><orcidid>https://orcid.org/0000-0002-1618-329X</orcidid><orcidid>https://orcid.org/0000-0002-0622-7682</orcidid></search><sort><creationdate>202002</creationdate><title>Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019</title><author>Nakamura, Yasuhiro ; Asai, Jun ; Igaki, Hiroshi ; Inozume, Takashi ; Namikawa, Kenjiro ; Hayashi, Ayato ; Fukushima, Satoshi ; Fujimura, Taku ; Ito, Takamichi ; Imafuku, Keisuke ; Tanaka, Ryota ; Teramoto, Yukiko ; Minagawa, Akane ; Miyagawa, Takuya ; Miyashita, Azusa ; Wada, Makoto ; Koga, Hiroshi ; Sugaya, Makoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5021-dbd5e7eb3959f71d02198c1ff0b3352234e8dd35da6c4edd5f1db2be5eac16283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Best practice</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>cutaneous melanoma</topic><topic>Dermatology - standards</topic><topic>grade system</topic><topic>guidelines</topic><topic>Humans</topic><topic>immune checkpoint inhibitor</topic><topic>Immune checkpoint inhibitors</topic><topic>Japan</topic><topic>Melanoma</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - therapy</topic><topic>molecular‐targeted agent</topic><topic>Patient Care Team - standards</topic><topic>Radiation Oncology - standards</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - diagnosis</topic><topic>Skin Neoplasms - therapy</topic><topic>Societies, Medical - standards</topic><topic>Surgery, Plastic - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Yasuhiro</creatorcontrib><creatorcontrib>Asai, Jun</creatorcontrib><creatorcontrib>Igaki, Hiroshi</creatorcontrib><creatorcontrib>Inozume, Takashi</creatorcontrib><creatorcontrib>Namikawa, Kenjiro</creatorcontrib><creatorcontrib>Hayashi, Ayato</creatorcontrib><creatorcontrib>Fukushima, Satoshi</creatorcontrib><creatorcontrib>Fujimura, Taku</creatorcontrib><creatorcontrib>Ito, Takamichi</creatorcontrib><creatorcontrib>Imafuku, Keisuke</creatorcontrib><creatorcontrib>Tanaka, Ryota</creatorcontrib><creatorcontrib>Teramoto, Yukiko</creatorcontrib><creatorcontrib>Minagawa, Akane</creatorcontrib><creatorcontrib>Miyagawa, Takuya</creatorcontrib><creatorcontrib>Miyashita, Azusa</creatorcontrib><creatorcontrib>Wada, Makoto</creatorcontrib><creatorcontrib>Koga, Hiroshi</creatorcontrib><creatorcontrib>Sugaya, Makoto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Yasuhiro</au><au>Asai, Jun</au><au>Igaki, Hiroshi</au><au>Inozume, Takashi</au><au>Namikawa, Kenjiro</au><au>Hayashi, Ayato</au><au>Fukushima, Satoshi</au><au>Fujimura, Taku</au><au>Ito, Takamichi</au><au>Imafuku, Keisuke</au><au>Tanaka, Ryota</au><au>Teramoto, Yukiko</au><au>Minagawa, Akane</au><au>Miyagawa, Takuya</au><au>Miyashita, Azusa</au><au>Wada, Makoto</au><au>Koga, Hiroshi</au><au>Sugaya, Makoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019</atitle><jtitle>Journal of dermatology</jtitle><addtitle>J Dermatol</addtitle><date>2020-02</date><risdate>2020</risdate><volume>47</volume><issue>2</issue><spage>89</spage><epage>103</epage><pages>89-103</pages><issn>0385-2407</issn><eissn>1346-8138</eissn><abstract>With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31782186</pmid><doi>10.1111/1346-8138.15151</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-7817-624X</orcidid><orcidid>https://orcid.org/0000-0002-7887-8126</orcidid><orcidid>https://orcid.org/0000-0001-7054-1863</orcidid><orcidid>https://orcid.org/0000-0002-8855-3288</orcidid><orcidid>https://orcid.org/0000-0003-2763-7346</orcidid><orcidid>https://orcid.org/0000-0002-4471-1635</orcidid><orcidid>https://orcid.org/0000-0002-2679-8546</orcidid><orcidid>https://orcid.org/0000-0002-0704-8037</orcidid><orcidid>https://orcid.org/0000-0002-7610-0820</orcidid><orcidid>https://orcid.org/0000-0003-4222-9762</orcidid><orcidid>https://orcid.org/0000-0001-6809-5833</orcidid><orcidid>https://orcid.org/0000-0002-3664-5818</orcidid><orcidid>https://orcid.org/0000-0003-2805-4177</orcidid><orcidid>https://orcid.org/0000-0001-7983-9746</orcidid><orcidid>https://orcid.org/0000-0002-5125-2932</orcidid><orcidid>https://orcid.org/0000-0002-1618-329X</orcidid><orcidid>https://orcid.org/0000-0002-0622-7682</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0385-2407 |
ispartof | Journal of dermatology, 2020-02, Vol.47 (2), p.89-103 |
issn | 0385-2407 1346-8138 |
language | eng |
recordid | cdi_proquest_miscellaneous_2320375878 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Best practice Cancer therapies Clinical trials cutaneous melanoma Dermatology - standards grade system guidelines Humans immune checkpoint inhibitor Immune checkpoint inhibitors Japan Melanoma Melanoma - diagnosis Melanoma - therapy molecular‐targeted agent Patient Care Team - standards Radiation Oncology - standards Skin cancer Skin Neoplasms - diagnosis Skin Neoplasms - therapy Societies, Medical - standards Surgery, Plastic - standards |
title | Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A45%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Japanese%20Dermatological%20Association%20Guidelines:%20Outlines%20of%20guidelines%20for%20cutaneous%20melanoma%202019&rft.jtitle=Journal%20of%20dermatology&rft.au=Nakamura,%20Yasuhiro&rft.date=2020-02&rft.volume=47&rft.issue=2&rft.spage=89&rft.epage=103&rft.pages=89-103&rft.issn=0385-2407&rft.eissn=1346-8138&rft_id=info:doi/10.1111/1346-8138.15151&rft_dat=%3Cproquest_cross%3E2320375878%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350130063&rft_id=info:pmid/31782186&rfr_iscdi=true |